Immuron Board Approves IMM-529 Cgmp Manufacturing And To Proceed With FDA Pre-IND Submission
Portfolio Pulse from Charles Gross
Immuron has approved proceeding with IMM-529 cGMP manufacturing and FDA pre-IND submission for the treatment of Clostridioides difficile infection (CDI), a life-threatening gastrointestinal disease.
June 21, 2023 | 11:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immuron's approval of IMM-529 cGMP manufacturing and FDA pre-IND submission may positively impact the company's stock price.
The approval of IMM-529 cGMP manufacturing and FDA pre-IND submission indicates progress in Immuron's product pipeline. This development may attract investors and positively impact the stock price of IMRN in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100